Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial

Publisher： Karger

E-ISSN： 1423-0232|76|1|49-54

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.1, 2008-11, pp. : 49-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 243-249

Karger

Access to resources Recommend Favorite

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-05 ,pp. : 433-437

Karger

Access to resources Recommend Favorite

A Study of Pegylated Liposomal Doxorubicin in Platinum-Refractory Epithelial Ovarian Cancer

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 183-186

Karger

Access to resources Recommend Favorite

Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 141-146

Karger

Access to resources Recommend Favorite